Pannexin 1 channel blockers
Blocking multiple pathways to transform
cancer therapy
PANNEX Therapeutics is pioneering the development of Pannexin 1 channel (Panx1) blockers, a new class of cancer drugs that block multiple pathways to stop growth, spread and survival of cancer cells.
Discover our science
Pannexin 1
The Pannexin 1 channel (Panx1) is a recently discovered and validated pharmacological target that plays a key role in multiple pathophysiological pathways of many types of cancer.
ScienceOur team
David Bravo PhD
Chief Executive Officer &
Co-founder
Pannexin 1 research leader with more than a decade of success in drug discovery and innovation
Thomas Gerlach PhD
Chief Strategic Officer &
Co-founder
Biochemist with over 30 years of experience in global drug development, commercialization and venture capital
Gerhard Gross PhD
Chief Scientific Officer &
Co-founder
Chemist with 30 years of experience in drug discovery and development - 14 FDA - approved drugs